These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
624 related articles for article (PubMed ID: 19060632)
21. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids. Yamamoto-Furusho JK; Uzcanga LF Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257 [TBL] [Abstract][Full Text] [Related]
22. Safety of infliximab in 10 years of clinical practice. O'Donnell S; Murphy S; Anwar MM; O'Sullivan M; Breslin N; O'Connor HJ; Ryan BM; O'Morain CA Eur J Gastroenterol Hepatol; 2011 Jul; 23(7):603-6. PubMed ID: 21602689 [TBL] [Abstract][Full Text] [Related]
23. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Schneeweiss S; Korzenik J; Solomon DH; Canning C; Lee J; Bressler B Aliment Pharmacol Ther; 2009 Aug; 30(3):253-64. PubMed ID: 19438424 [TBL] [Abstract][Full Text] [Related]
24. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease. Babouri A; Buisson A; Bigard MA; Peyrin-Biroulet L J Crohns Colitis; 2013 Mar; 7(2):129-33. PubMed ID: 22472090 [TBL] [Abstract][Full Text] [Related]
25. Management of Crohn's disease of the ileoanal pouch with infliximab. Colombel JF; Ricart E; Loftus EV; Tremaine WJ; Young-Fadok T; Dozois EJ; Wolff BG; Devine R; Pemberton JH; Sandborn WJ Am J Gastroenterol; 2003 Oct; 98(10):2239-44. PubMed ID: 14572574 [TBL] [Abstract][Full Text] [Related]
26. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882 [TBL] [Abstract][Full Text] [Related]
27. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Jahnsen J; Detlie TE; Vatn S; Ricanek P Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534 [TBL] [Abstract][Full Text] [Related]
28. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R; Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398 [TBL] [Abstract][Full Text] [Related]
29. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465 [TBL] [Abstract][Full Text] [Related]
30. The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. Moss AC; Fernandez-Becker N; Jo Kim K; Cury D; Cheifetz AS Aliment Pharmacol Ther; 2008 Jul; 28(2):221-7. PubMed ID: 18485127 [TBL] [Abstract][Full Text] [Related]
31. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545 [TBL] [Abstract][Full Text] [Related]
32. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Kohn A; Daperno M; Armuzzi A; Cappello M; Biancone L; Orlando A; Viscido A; Annese V; Riegler G; Meucci G; Marrollo M; Sostegni R; Gasbarrini A; Peralta S; Prantera C Aliment Pharmacol Ther; 2007 Sep; 26(5):747-56. PubMed ID: 17697208 [TBL] [Abstract][Full Text] [Related]
33. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684 [TBL] [Abstract][Full Text] [Related]
34. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease. Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037 [TBL] [Abstract][Full Text] [Related]
35. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation. Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175 [TBL] [Abstract][Full Text] [Related]
36. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. Duron C; Goutte M; Pereira B; Bommelaer G; Buisson A Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):705-11. PubMed ID: 25856689 [TBL] [Abstract][Full Text] [Related]
37. Predictors of infusion reactions during infliximab treatment in patients with arthritis. Kapetanovic MC; Larsson L; Truedsson L; Sturfelt G; Saxne T; Geborek P Arthritis Res Ther; 2006; 8(4):R131. PubMed ID: 16869978 [TBL] [Abstract][Full Text] [Related]
38. [Optimizing effect of infliximab upon inflammatory bowel disease]. Li SR; Sheng JQ; Li SJ; Zhao XJ Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621 [TBL] [Abstract][Full Text] [Related]
39. Safety and effectiveness of infliximab for inflammatory bowel diseases in clinical practice. Tursi A; Elisei W; Brandimarte G; Giorgetti G; Penna A; Castrignano V Eur Rev Med Pharmacol Sci; 2010 Jan; 14(1):47-55. PubMed ID: 20184089 [TBL] [Abstract][Full Text] [Related]